Dr. Graham Merry, Aleafia Health Inc.’s first-ever product data science fellow, will lead the company’s ongoing medical cannabis research efforts into the development of evidence-based, proprietary treatment methods and products for chronic illnesses.
Leveraging Aleafia Health’s proprietary, 10 million-point medical cannabis patient dataset, Dr. Merry will guide medical cannabis research into chronic illnesses such as pain, insomnia, anxiety and eating disorders, notes a statement from the company.
A graduate in medicine from The Royal London Hospital Medical College in London, and founder of Photospectra Health Sciences Inc., his appointment “is part of a global initiative by Aleafia Health to build an integrated, scalable cannabis consumer experience, leveraging the company’s in-house, executive leadership experience at multi-billion dollar eCommerce and IT companies.”
Current Aleafia Health research initiatives include an insomnia study in partnership with Cronos Group, a cannabinoid pharmacogenetics study with Guided 420 Genetics and AKESOgen and a recently published study on cannabis and benzodiazepines.
Dr. Merry “has instigated, been a principal investigator and published clinical trials internationally,” reports Aleafia Health, a vertically integrated, national cannabis company that operates a major medical clinic, cannabis cultivation and research and development facilities.
“Aleafia Health tracks all patient interactions with referring doctors, nurse practitioners and educators from diagnosis, treatment, monitoring and continuous learning,” the company notes. It “generated $0.6 million in research revenue in Q3 2018 alone, fuelled primarily by medical cannabis companies subscribing to Aleafia Health’s proprietary medical cannabis patient dataset,” the statement adds.
“We will enable patients to navigate seamlessly through cannabis education, illness-specific questionnaires, medical cannabis script product purchasing, order subscription management and treatment/titration monitoring, says company CEO Geoffrey Benic.
“We will continue to make important contributions to the research of medical cannabis treatment best practices and product development,” comments Dr. Michael Verbora, Aleafia Health’s chief medical officer.
“This initiative will allow the opportunity to obtain clinical evidence to validate and gain wider acceptance in the medical community realizing the benefits of cannabinoid treatment in serious and debilitating disease,” Dr. Merry says. “Together, we will make a huge difference in addressing the unmet needs of patients in this emerging field of medicine,” he notes.
Also at Aleafia Health, Dr. Taylor Lougheed, who has an extensive history in cannabinoid prescribing as the lead physician at Ottawa’s Canabo Medical Clinic, has been appointed as physician lead for QI/QA of clinic operations.
“Dr. Lougheed will help drive efficiencies across a growing clinic network and leverage Aleafia proprietary research data to optimize clinical decision-making to maximize cannabinoid therapy outcomes for patients,” the company statement adds